Faculty Opinions recommendation of PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.

2015 ◽  
Author(s):  
Michele Spina
Keyword(s):  
Salvage Therapy ◽  
Hodgkin’S Lymphoma ◽  
Brentuximab Vedotin ◽  
Hodgkin's Lymphoma ◽  
Phase 2 ◽  
Single Centre ◽  
Open Label ◽  
Phase 2 Study

scholarly journals Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

2011 ◽  
Vol 12 (13) ◽  
pp. 1222-1228 ◽  
Author(s):  
Anas Younes ◽  
Yasuhiro Oki ◽  
R Gregory Bociek ◽  
John Kuruvilla ◽  
Michelle Fanale ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Trial

scholarly journals Design of a Phase 2 STudy of Brentuximab Vedotin (SGN-35) as Salvage Therapy for Males with Chemoresistant Germ-Cell Tumors (GCT)

2014 ◽  
Vol 25 ◽  
pp. vi3
Author(s):  
P. Giannatempo ◽  
A. Anichini ◽  
D. Raggi ◽  
E. Cordareschi ◽  
N. Nicolai ◽  
...  
Keyword(s):  
Germ Cell ◽  
Salvage Therapy ◽  
Germ Cell Tumors ◽  
Brentuximab Vedotin ◽  
Phase 2 ◽  
Phase 2 Study

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study

2013 ◽  
Vol 14 (13) ◽  
pp. 1348-1356 ◽  
Author(s):  
Anas Younes ◽  
Joseph M Connors ◽  
Steven I Park ◽  
Michelle Fanale ◽  
Megan M O'Meara ◽  
...  
Keyword(s):  
Dose Escalation ◽  
Hodgkin’S Lymphoma ◽  
Phase 1 ◽  
Brentuximab Vedotin ◽  
Hodgkin's Lymphoma ◽  
Newly Diagnosed ◽  
Open Label ◽  
Dose Escalation Study ◽  
Label Dose
Sign in / Sign up

Export Citation Format

Share Document